Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome-Reference-Cited by-同舟云学术

Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome

Published:2020-01-01 Issue:1 Volume:9 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Brunekreeft Kim L.¹,Paijens Sterre T.¹,Wouters Maartje C.A.²,Komdeur Fenne L.¹,Eggink Florine A.¹,Lubbers Joyce M.¹,Workel Hagma H.¹,Van Der Slikke Elisabeth C.¹,Pröpper Noor E.J.¹,Leffers Ninke¹,Adam Julien³,Pijper Harry¹,Plat Annechien¹,Kol Arjan¹,Nijman Hans W.¹^ORCID,De Bruyn Marco¹

Affiliation:

1. Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, The Netherlands

2. Trev and Joyce Deeley Research Centre, BC Cancer, BC Cancer, Victoria, Canada

3. Department of Clinical Biology, Institut De Cancérologie Gustave Roussy, Paris, France

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2020.1760705

Reference43 articles.

1. Rethinking ovarian cancer: recommendations for improving outcomes